NASDAQ:BBHVanEck Vectors Biotech ETF Stock Price, Forecast & News

VanEck Vectors Biotech ETF's stock was trading at $126.82 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BBH stock has increased by 25.4% and is now trading at $159.08.
View which stocks have been most impacted by Coronavirus.

News headlines about BBH stock have been trending negative recently, InfoTrie reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. VanEck Vectors Biotech ETF earned a news impact score of -2.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about VanEck Vectors Biotech ETF.

VanEck Vectors Biotech ETF saw a increase in short interest in January. As of January 31st, there was short interest totaling 50,200 shares, an increase of 12.6% from the January 15th total of 44,600 shares. Based on an average trading volume of 14,700 shares, the days-to-cover ratio is currently 3.4 days.
View VanEck Vectors Biotech ETF's Short Interest.

Some companies that are related to VanEck Vectors Biotech ETF include Adams Diversified Equity Fund (ADX), PIMCO Corporate&Income Opportunity Fund (PTY), Tri-Continental (TY), Royce Value Trust (RVT), Hercules Capital (HTGC), Gabelli Equity Trust (GAB), Liberty All-Star Equity Fund (USA), Boulder Growth & Income Fund (BIF), Tortoise Energy Infrastructure (TYG), Blackrock Muniyield Insured Fund (MYI), AllianceBernstein Global Hgh Incm Fd (AWF), Tekla Healthcare Investors (HQH), Invesco Van Kampen Munpl Oprtnty Tr (VMO), General American Investors (GAM) and Templeton Dragon Fund (TDF).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other VanEck Vectors Biotech ETF investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Sanofi (SNY), Cidara Therapeutics (CDTX), Intel (INTC), (MRNA), Micron Technology (MU), Pfizer (PFE), Quest Diagnostics (DGX) and Novavax (NVAX).

VanEck Vectors Biotech ETF trades on the NASDAQ under the ticker symbol "BBH."

VanEck Vectors Biotech ETF's stock is owned by many different retail and institutional investors. Top institutional investors include UBS Group AG (1.35%), Murphy Capital Management Inc. (1.10%), Envestnet Asset Management Inc. (0.62%), HighTower Advisors LLC (0.47%), Boston Research & Management Inc. (0.46%) and Raymond James & Associates (0.46%).

BBH stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Murphy Capital Management Inc., Aspiriant LLC, Boston Research & Management Inc., Telemus Capital LLC, and Tufton Capital Management.

BBH stock was purchased by a variety of institutional investors in the last quarter, including LFA Lugano Financial Advisors SA, Envestnet Asset Management Inc., Wedbush Securities Inc., Columbus Macro LLC, Raymond James & Associates, Prudential PLC, Raymond James Financial Services Advisors Inc., and Cambridge Investment Research Advisors Inc..

Shares of BBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BBH stock can currently be purchased for approximately $159.08.

VanEck Vectors Biotech ETF has a market capitalization of $492.67 million.